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Abstract IL-5 is the primary cytokine that stimulates the production and survival of eosinophils and basophils from pro-
genitor cells. The inhaled glucocorticoid, budesonide, has been shown to exert a therapeutic effect via suppression of 
eosinophil/basophil progenitors in vivo. Since various steroids have exhibited the ability to enhance eosinophil/basophil 
progenitor differentiation, we examined the effects of budesonide in vitro. Bone marrow and cord blood samples were ob-
tained and cultured in the presence of IL-5 alone or IL-5 plus budesonide. Eosinophil/basophil colony-forming units were 
enumerated from cultured nonadherent mononuclear cells and from purified CD34
+ cells. CD34
+ cells with and without 
budesonide were also examined for up-regulation of ERK1/2, MAPK and GATA-1 using real time-PCR. Results: i) up-
regulation of eosinophil/basophil colony-forming units is due to the direct effects of budesonide on IL-5-stimulated pro-
genitors; ii) GATA-1 is likely involved in the early amplification of eosinophil/basophil progenitor commitment leading 
to increased differentiation. A potential transcriptional pathway has been identified which may mediate the effects of 
budesonide on eosinophil/basophil lineage commitment. 
Keywords: Budesonide, eosinophil/basophil progenitors, corticosteroids, GATA-1, IL-5. 
INTRODUCTION 
  An increase in tissue eosinophils is one of the most char-
acteristic features of allergic inflammation. Eosinophils 
share a common progenitor with basophils, identified func-
tionally as eosinophil/basophil colony-forming units (Eo/B 
CFU), which grow in semi-solid media in the presence of 
cytokines including IL-3, IL-5, and GM-CSF [1,2]. Of these 
cytokines, IL-5 plays a particularly important role in the 
eosinophil/basophil lineage-commitment of progenitor cells 
[3]. 
  Our group and others have illustrated the involvement of 
Eo/B progenitors in allergic inflammatory disease in the fol-
lowing studies: i) increases in circulating Eo/B CFU in sub-
jects with atopy and allergic rhinitis [1,4]; ii) increases in 
circulating Eo/B CFU during seasonal exposure to allergens 
[5,6]; iii) increases in circulating and bone marrow progeni-
tors and upregulation of IL-5R expression after allergen 
inhalation challenge [7-10] and iv) increases in airway 
CD34
+ cells expressing the IL-5R after allergen inhalation 
[11]. 
  Corticosteroids are currently the most effective therapy in 
the treatment of asthma, acting at least in part through the 
suppression of Eo/B progenitors in vivo [9,12,13]. Inhaled 
steroids have been shown to decrease circulating Eo/B CFU 
[14] and to attenuate increases in circulating Eo/B CFU [13]  
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in subjects with asthma. Moreover, the controlled, step-wise 
withdrawal of inhaled corticosteroids in atopic asthmatics 
leads to a rapid and sustained increase in peripheral blood 
Eo/B CFU, coinciding with the development of asthmatic 
symptoms and with peak-flow changes; the re-introduction 
of inhaled corticosteroids, conversely leads to resolution of 
symptoms, accompanied by a decrease in circulating eosino-
phils, basophils and Eo/B CFU [12]. In an allergen-challenge 
model studying subjects with asthma, a short course of in-
haled corticosteroids leads to a decrease in the baseline num-
ber of bone marrow CD34
+IL-5R
+ eosinophil progenitors 
and IL-5-responsive Eo/B CFU; interestingly however, in-
haled corticosteroids do not prevent allergen-induced in-
creases of either [9]. Thus, while topical corticosteroids exert 
suppressive effects on the differentiation of eosinophil pro-
genitors [9,12,13], this is probably via the regulation of tis-
sue cytokine expression [15], a mode of suppression insuffi-
cient to fully abrogate the marrow contribution to eosinophil 
recruitment in vivo. 
  Indeed, stimulatory effects of steroids on eosinophil 
growth and differentiation have been observed since the 
1950s in vitro [16]. Studies of bone marrow cultures indicate 
that at physiological and pharmacological concentrations, 
hydrocortisone is able to stimulate eosinophilopoiesis [17]. 
More recently, others have shown, using a murine model, 
that glucocorticoids enhance bone marrow eosinophilopoie-
sis in normal and allergic mice [18]; the latter group also 
demonstrated that pre-treatment of these mice with dex-
amethasone for 24 hours in vivo resulted in increased pro-
genitor responses to both GM-CSF and IL-5 ex vivo. These 
studies indicate a direct, stimulatory effect of corticosteroids 
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  Corticosteroids have revolutionized the treatment of 
asthma and their anti-inflammatory effects are exerted 
through multiple pathways. Perhaps because of their signifi-
cant effectiveness, researchers have only recently begun ex-
amining the potential limitations of corticosteroids in the 
treatment of asthma. The ability of corticosteroids to prevent 
airway remodeling is conflicting [19] and recently it has 
been demonstrated in a murine model of asthma, that corti-
costeroids are not only unable to prevent mucosal sensitiza-
tion but may indeed enhance the allergic response upon al-
lergen rechallenge [20]. 
  In this study, we examine the in vitro effects of a clini-
cally active, topical corticosteroid, budesonide (BUD), on 
Eo/B CFU formation. We show evidence for enhancement of 
IL-5-mediated eosinophil growth and differentiation, and 
suggest an effect on the Eo/B lineage-specific transcription 
factor, GATA-1, as a possible explanation for this enhance-
ment. 
MATERIALS AND METHODS 
  This study was approved by the Hamilton Health Sci-
ences/McMaster University Faculty of Health Sciences Re-
search Ethics Board, and subjects provided written informed 
consent to participate. 
Collection and Processing of Bone Marrow 
  Bone marrow aspirates (2-3 ml) were collected by a he-
matologist, from the iliac crest of human subjects using a 
bone marrow aspiration needle (16 x 2 inches; Sherwood 
Medical, St. Louis, Mo), into a 10ml syringe containing 1ml 
of sterile heparin (1000 Units/ml; Sigma Chemical Co., St. 
Louis, MO). Bone marrow was then transferred to a 50ml 
Falcon tube and diluted to 50ml with McCoy’s 5A (Gibco, 
New York, USA). 
Collection and Processing Cord Blood Cells 
  Cord blood was collected in a 60ml syringe containing 
2ml of sterile heparin (1000 Units/ml; Sigma-Aldrich, 
Oakville, Canada). Red blood cells were sedimented with 
1% Dextran (Sigma-Aldrich) at 37°C for 30 minutes and 
white cells were removed and diluted 1:1 with McCoy’s 5A 
(Gibco). 
Non-Adherent Mononuclear Cell Isolation 
  White cells were layered over Accuprep (Accurate 
Chemical and Scientific Corp., New York, USA) and sub-
jected to density gradient separation (2000rpm for 20 min-
utes at room temperature). Mononuclear cells were removed 
and washed (1500 rpm for 10 minutes at room temperature) 
in McCoy’s 5A (Gibco). After washing, cells were re-
suspended in McCoy’s 5A supplemented with 15% FBS 
(Sigma-Aldrich), 1% Penicillin-Streptomycin (Gibco) and 
1% 2-ME, and incubated at 37°C and 5% CO2 in a plastic 
flask (Corning Inc., New York, USA) for 2 hours at 1x10
6 
mononuclear cells/ml. The remaining non-adherent mononu-
clear cells (NAMNC) were collected and washed. 
CD34
+ Progenitor Cell Isolation 
 CD34
+ progenitor cells were isolated from NAMNC us-
ing a CD34 progenitor cell isolation kit (Miltenyi Biotec, 
Auburn, CA) via  indirect labeling and positive selection 
techniques [21]. NAMNC were washed once in cold mag-
netic activated cell sorting (MACS) buffer and then re-
suspended in cold MACS buffer. NAMNC were incubated 
with a blocking antibody and primary anti-CD34 
(QBEND/10 epitope) hapten-conjugated antibody for 15 
minutes at 4°C. Cells were then washed once and re-
suspended in cold MACS buffer. NAMNC were then mag-
netically labeled via incubation with a secondary anti-hapten 
Microbead conjugated antibody. Labeled cells were then 
washed, re-suspended and then run through a MS column 
using the MiniMACS system (Miltenyi Biotec). The positive 
fraction was eluted in McCoy’s 3
+. The total number of 
CD34
+ cells was determined by performing a cell count us-
ing a hemocytometer (Neubauer Chamber, Hausser Scien-
tific). 
Methylcellulose Colony Assays 
  Methylcellulose colony assays for bone marrow and cord 
blood (CB) Eo/B CFU were performed as previously de-
scribed using peripheral blood [4]. Bone marrow NAMNC 
were cultured at 2.5 x 10
5 cells per 35 x 10-mm tissue culture 
dish (Falcon Plastics, Oxnard, CA) with IL-5 (10ng/ml) 
(Pharmingen, Markham, ON, Canada) ± BUD (10
-8-10
-7) 
(AstraZeneca, Lund, Sweden). Cells were cultured in 0.9% 
methylcellulose (Sigma) with Iscove’s modified Dulbecco’s 
medium (Gibco) and 20% fetal bovine serum supplemented 
with 1% penicillin-streptomycin and 5 x 10
-5 M 2-
mercaptoethanol. CB CD34
+ cells were cultured at 8 x 10
3 
per 35 x 10-mm tissue culture dish in the presence of IL-5 (1 
ng/ml) ± BUD (10
-9-10
-7). 
  Cultures were incubated for 14 days at 37 °C and 5% 
CO2. Day 14 Eo/B type granulocyte colonies (>40 cells) 
were enumerated in two replicate methylcellulose plates un-
der inverted light microscopy and expressed as Eo/B CFU 
per cells plated. The Eo/B colonies were identified by mor-
phology as tight, granulated, round, refractile cell aggrega-
tions [1,22]. 
Flow Cytometric Specific Mean Fluorescence Intensity 
(sMFI) Assay of CB CD34
+ Cells 
 Isolated  CD34
+ cells were stimulated with IL-5 (1 ng/ml) 
alone, or IL-5 (1 ng/ml) with BUD (10
-8M), and incubated in 
RPMI complete (10
6 cells/ml; Gibco) in plastic flasks for 24 
hours at 37°C and 5% CO2. After stimulation, CB CD34
+ 
cells were stained and analyzed by flow cytometry as previ-
ously described [10]. Briefly, cells were washed with cold 
0.1% PBS/NaN3 solution (PBS containing 0.1% NaN3 and 
0.5% BSA; Sigma). A minimum 50 x 10
3 CD34
+ cells per 
tube were stained with saturating amounts of biotinylated 
anti-IL-5R (Roche Laboratories, Ghent, Belgium) or bi-
otinylated IgG1 isotype control antibodies (Becton Dickin-
son, Mississauga, Ontario, Canada) for 30 minutes at 4°C. 
The cells were then washed and stained with streptavidin-
conjugated Cychrome (Becton Dickinson), along with satu-
rating concentrations of anti-CD45 FITC (Becton Dickinson) 
and anti-CD34-PE (Becton Dickinson) in a final volume of 
100 μl of 0.1% PBS/NaN3 solution for 30 minutes at 4°C. 
Cells were then washed and fixed in 500 μl of PBS contain-
ing 1% paraformaldehyde (Sigma). Stained cells were stored 
in the dark at 4°C until ready for analysis. Stained cells were 
analyzed using a FACScan flow cytometer (Becton Dickin-
son Instrument Systems, BDIS, Mississauga, Canada). Each 
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sis of the acquired data was performed using the PC lysis 
software (BDIS). The sMFI of the IL-5R was obtained by 
subtracting the MFI of the isotype control from the MFI for 
the IL-5R for both stimulated and unstimulated samples. 
Signal Molecule Activation Assay 
  Stimulated and un-stimulated bone marrow CD34
+ cells 
were lysed in RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 
mM NaCl, 1 mM EGTA, 0.25% sodium-deoxycholate, 1 μM 
PMSF, 1 μM Na3VO4, 1 mM NaF, 0.7% Triton X-100, and 1 
μg/ml of aprotinin, leupeptin, and pepstatin). Immunopre-
cipitation and Western blotting assays were performed as 
previously described [23]. Briefly, cell lysates were passed 
through a 26-gauge needle several times and detergent-
insoluble materials were removed via centrifugation at 4°C 
and 12,000 x g. The protein concentration was then deter-
mined using a bicinchoninic acid assay (Pierce, Rockford, 
IL). Cell lysates were then immunoprecipitated with anti-p38 
MAPK or anti-ERK 1/2 antibodies (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and subsequently resolved on an SDS-
PAGE for analysis. The immunoprecipitate was then West-
ern blotted with the anti-phosphotyrosine antibody (Upstate 
Biotechnology, Lake Placid, NY) to obtain a measure of the 
activation, as measured through phosphorylation, of p38 
MAPK and ERK 1/2. 
Cell Stimulation, RNA Extraction and Reverse Tran-
scription 
  CB NAMNC were incubated at 1x10
6 NAMNC cells/ml 
in 100 x 20mm culture plates (Falcon Plastics, New Jersey, 
USA) at 37°C, 5% CO2 in the presence or absence of recom-
binant human IL-5 (1ng/ml) with or without 10¯
8M BUD at 
varying time points. After stimulation, ice cold PBS was 
added, and cells were pelleted in a 15ml centrifuge tube 
(Sarstedt) at 1500rpm for 5 minutes at 4°C. The supernatant 
was poured off and RNA extracted using the Qiagen RNeasy 
mini-kit protocol for animal cells (Qiagen, Mississauga, 
Canada). Isolated RNA was treated with DNA-free (Ambion 
Inc., Canada), and the amount and purity determined using 
UV spectrophotometry (Ultrospec 2000, Fisher Scientific, 
Toronto, Canada). Two μg of total RNA from each condition 
was reverse transcribed using Oligo (dT) primers (StrataS-
cript First-Strand Synthesis System, Stratagene, La Jolla, 
California, USA), and resulting cDNA diluted 1:5 with Ul-
traPure distilled water (Gibco). 
Quantitative Real-Time PCR (Q-PCR) 
  Real-time PCR was carried out using the MX4000 ma-
chine (Stratagene), with SYBR Green chemistry (Stratagene) 
and run as a comparative quantitation experiment with 
GATA-1 primers (Search LC, Heidelberg, Germany). Posi-
tive and no-template controls, and the normalizing gene 
GAPDH (IDT, Iowa, USA) forward 5’- GAGTCAACG-
GATTTGGTGT–3’, reverse GATTTTGG- AGGGACTCG 
3’ were included with Human Reference Total RNA 
(Stratagene) used as a standard. Q-PCR reactions were set up 
as follows: 4ng cDNA was added to 12.5 μl 2x SYBR Green 
Master Mix, 100nM of forward and reverse primers and 
30nM reference dye, giving a final volume of 25 μl. PCR 
cycles were 10 minutes at 95°C and 40 amplification cycles 
(95°C for 30 seconds and 55°C for 30 seconds). Target genes 
were confirmed using northern blot analysis, and the fold 
increase in GATA-1 gene expression between un-stimulated 
and stimulated cells was determined using the 2¯Ct 
method [24]. 
Statistics 
  All summary statistics are expressed as the mean ± SEM. 
For colony data, the mean colony counts are represented as 
the mean change from baseline (baseline was characterized 
as IL-5 alone). Group mean comparisons were performed on 
the absolute numbers using repeated measures analysis of 
variance (ANOVA). Statistical significance was assumed at 
a P value of less than 0.05. GATA-1 mRNA expression is 
reported as mean GATA-1 fold increases of Ct of cells 
stimulated with IL-5 over un-stimulated cells. Comparisons 
between groups were made with ANOVA. 
RESULTS 
The Effects of BUD on IL-5-Responsive BM NAMNC 
  The addition of BUD at concentrations of 10
-9M to 10
-7M 
caused a significant increase in IL-5-responsive Eo/B-CFU, 
compared to IL-5 alone (p<0.001) (Fig. 1). In addition, pre-
incubation of bone marrow cells with BUD (10
-9M) prior to 
the addition of IL-5 also increased the number of Eo/B-CFU, 
compared to diluent control (p<0.0001) (data not shown). 
 
Fig. (1). The effect of BUD on IL-5 stimulated bone marrow 
NAMNC. Error bars represent SEM (N= 34) (** p < 0.001). 
The Effects of BUD on IL-5- Responsive CB CD34
+ Pro-
genitors 
  The addition of BUD, at concentrations of 10
-9M to   
10
-7M caused an increase in IL-5-responsive Eo/B CFU 
compared to IL-5 alone reaching statistical significance at 
10
-8M (p<0.001) (Fig. 2). 
The Effects of BUD on the IL-5R Intensity Expression 
on CB-Derived CD34
+ Progenitor Cells and Bone Mar-
row NAMNC 
  The addition of BUD had no effect on the expression of 
IL-5R on CB-derived CD34
+  cells or bone marrow 
NAMNC, as measured by flow cytometry (data not shown). 
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Fig. (2). The effect of BUD on IL-5 stimulated CB-derived CD34+ 
progenitor cell differentiation. Error bars represent SEM (N=8)   
(*p < 0.001). 
The Effects of BUD on IL-5-Transduced Activation of the 
Signaling Molecules p38 and ERK 1/2 Using Bone Mar-
row-Derived CD34
+ Progenitor Cells 
  The addition of BUD at concentrations of 10
-8M was 
shown to have no effect in either stimulating or inhibiting 
signal molecule activation, transduced via IL-5 interaction 
with IL-5R (N=3). Western blot analysis showed that 
phosphorylation of ERK 1/2 was detected in only one out of 
three samples stimulated with IL-5 at a concentration of 
1ng/ml (lane 9, Fig. 3a). 
  The addition of BUD, at a concentration of 10
-8M, was 
shown to have no effect on the phosphorylation of ERK 1/2 
in any of the three samples (lanes 4, 7 and 10; Fig. 3a). 
Western blot analysis indicated that p38 MAPK was acti-
vated in only one of the three samples stimulated with IL-5 
at a concentration of 1 ng/ml (lane 6, Fig. 3b). 
The Effect of BUD on GATA-1 mRNA Expression 
  IL-5 alone induces GATA-1 up-regulation in CB 
NAMNC, which peaks at 48 hours post-stimulation, with a 
12.3 fold (±4.3) increase from baseline. The addition of 
BUD at a concentration of 10
-8M resulted in an early en-
hancement of GATA-1 expression at 4 hours, with a fold 
increase of 11.5 (±6.8), followed by an inhibitory effect at 8 
hours (3.2±1.3), returning to baseline levels at 24 hours 
(2.4±1.0). All results are in comparison to un-stimulated CB 
cells (Fig. 4). 
DISCUSSION 
  Topical corticosteroids are currently the gold standard of 
therapy for the treatment of allergic diseases such as asthma 
and allergic rhinitis. They have potent effects in vivo, exert-
ing their effects on a wide array of cell types, including Eo/B 
progenitors, which produce the predominant effector cell in 
allergic inflammation. 
 
Fig. (3). (a) The effect of BUD on the phosphorylation of ERK1/2. 
Bone marrow CD34
+ cells were stimulated with IL-5 in the pres-
ence or absence of BUD (10
-8M). Western blot using anti-ERK 
antibodies show that there is phosphorylation in sample three only 
(lane 9) and BUD has no effect (lane 10). (b) The effect of BUD on 
the phosphorylation of p38 MAPK. Bone marrow CD34
+ cells were 
stimulated with IL-5 in the presence or absence of BUD (10
-8M). 
Western blot using anti-p38 antibodies show that there is phos-
phorylation in sample two only (lane 6) and BUD has no effect 
(lane 7). 
 
 
Fig. (4). Effect of BUD on IL-5-stimulated GATA-1 expression. 
The graph summarizes the kinetics of GATA-1 expression in IL-5-
stimulated CB hemopoietic progenitors. The effect of BUD on 
GATA-1 is shown in hatched bars. 
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  One of the aims of this study was to assess in vitro the 
direct effects of the glucocorticoid, BUD, on IL-5-mediated 
differentiation of bone marrow and CB-derived Eo/B pro-
genitors. Our results show an increase in the number of line-
age-committed, IL-5-responsive Eo/B progenitors, defined 
as an enhancement in Eo/B CFU, in the presence of BUD. 
  These results may appear counterintuitive, since inhaled 
steroid treatment has been shown to have a suppressive ef-
fect on circulating, bone marrow and tissue hemopoietic 
progenitors [9,12]. Inhibition of Eo/B progenitors has also 
been seen in tissue samples, since intranasal corticosteroid 
treatment results in increased CD34
+/CD45
+ cell immu-
nostaining in nasal polyp sections; this is interpreted as evi-
dence for arrested CD34
+ differentiation, since there is ac-
companying reduction of mature eosinophil numbers in tis-
sue [25]. In this context, it is important to note that airway 
eosinophils, while clearly markers of airway inflamma-
tion/exacerbation risk, may not always be directly involved 
in the pathogenesis of asthma, as evidenced by studies re-
porting persistent asthmatic responses in patients despite 
near ablation of blood and tissue eosinophils by anti-IL-5 
therapy [26]; this could also be related to the incomplete 
effect of anti-IL-5 on eosinophil differentiation [27], or to 
confounding corticosteroid effects, or to a combination of 
these factors. In addition, Kuo et al. [28] have shown that in 
cultures of peripheral blood non-adherent, non-T-cell popu-
lations, dexamethasone at 10
-6M causes a significant de-
crease in eosinophil CFU; however, these cultures were not 
supplemented with an exogenous colony stimulating factor, 
which likely accounts for the conflicting results. 
 Other in vitro studies have also given some conflicting 
data on the role of corticosteroids on eosinophils and their 
progenitors. For example, the addition of hydrocortisone   
(10
-5M) to cultures of peripheral blood and bone marrow 
NAMNC, resulted in greater than 95% inhibition in eosino-
phil colony formation [29]. Slovick et al. demonstrated, us-
ing unfractionated bone marrow, an inhibition in the number 
of eosinophil colonies in cultures with hydrocortisone at 
10
-6M [15]. Of note in this latter study, hydrocortisone at the 
same concentration and in the presence of conditioned media 
(a source of colony stimulating activity), actually stimulated 
an increase in eosinophil colonies in bone marrow depleted 
of monocytes and T cells. Barr et al. [17] described the en-
hancing effects of physiological and pharmacological con-
centrations of hydrocortisone (10
-7M and 10
-6M) in increas-
ing eosinophil colony numbers from cultures of human bone 
marrow. This was further substantiated by Butterfield et al. 
[30] who showed that incubation of bone marrow cells with 
micromolar concentrations of hydrocortisone resulted in a 
stimulation of eosinophil colony numbers. It was also shown 
in that study that administration of oral prednisone, while 
causing a significant decrease in bone marrow and peripheral 
blood eosinophil numbers, was not able to inhibit peripheral 
blood and bone marrow eosinophil colony numbers, thereby 
supporting the pro-eosinopoietic role of corticosteroids. 
  In a murine model, Gaspar Elsas et al. [18] demonstrated 
that the addition of dexamethasone (10
-7M) to cultures of 
bone marrow from naïve mice caused a significant increase 
in GM-CSF-induced myeloid colony formation. Specifically, 
dexamethasone at 10
-8M and 10
-7M, resulted in a significant 
increase both in the frequency of pure eosinophil colonies 
and in the size of eosinophil colonies. In order to confirm 
these results, normal, naïve mice were administered dex-
amethasone  in vivo, and bone marrow was harvested 24 
hours later. Cultures of bone marrow cells yielded an in-
crease in GM-CSF-induced colony formation, as well as in 
eosinophil colony size. Therefore, both in vitro and in vivo 
treatment with dexamethasone can result in selective en-
hancement of the eosinophil lineage and in myelopoiesis in 
general. 
  As a means of identifying a potential mechanism of the 
enhancing action of BUD on IL-5-mediated Eo/B differen-
tiation, we focused on two mechanisms which increase IL-5 
signaling through IL-5R on progenitor cells. The first, the 
expression of IL-5R on CD34+ progenitor cells, was exam-
ined since there is an increase in the proportion of bone mar-
row CD34
+ progenitor cells expressing IL-5R 24 hours 
after allergen challenge in asthmatic subjects [10], and pre-
treatment with BUD in vivo partially reduces baseline levels 
of CD34
+IL-5R
+ bone marrow cells, but does not abrogate 
the allergen-induced upregulation [9]. Upham et al. demon-
strated that the retinoic acid-induced reduction in the number 
of cells expressing IL-5R is accompanied by a reduction in 
the intensity of expression as measured by relative fluores-
cence intensity [31]. However, our current results indicate 
that BUD, at 10
-8M, is unable to stimulate an increase in the 
intensity of expression of IL-5R on CB CD34
+ progenitor 
cells as measured by sMFI. As a result, we conclude that 
BUD does not mediate its enhancing effects via increased 
IL-5R up-regulation or receptor density expression. 
  The second mechanism examined was the effect of BUD 
on IL-5 signaling via IL-5R. IL-5 signal transduction has 
been characterized previously by Adachi and Alam [32]. 
There are two main pathways of IL-5 signal transduction, the 
Ras-MAPK pathway and the JAK-STAT pathway [23,33]. 
IL-5 signaling via the Ras-MAPK pathway, specifically on 
the phosphorylation and activation of the ERK 1/2 and p38 
signaling molecules, is critical for eosinophil function, in-
cluding eosinophil survival, activation, degranulation and 
chemotaxis [23,34,35]. We hypothesized that BUD may me-
diate its enhancing effects via increased IL-5 signaling, and 
that this would lead to an increase in signaling molecules 
p38 and ERK 1/2 phosphorylation and activation. Our results 
demonstrated that in those samples where there was IL-5-
transduced phosphorylation of p38 MAPK or ERK 1/2, the 
addition of BUD resulted in no measurable increases in 
phosphorylation by Western blotting. One possible problem 
is that we were unable to consistently attain baseline levels 
of IL-5-induced phosphorylation in our samples. However, 
there is no a priori evidence to suggest that BUD would 
cause an inhibition of p38 MAPK or ERK 1/2 phosphoryla-
tion, and this is supported by the fact that IL-5 signaling 
events are necessary for the observed BUD enhancing ef-
fects. With the numerous pathways and signaling molecules 
involved in the IL-5 signal transduction cascade, we are not 
able to definitively eliminate increased signaling through 
p38 MAPK or ERK 1/2 as a mechanism for our observed 
BUD-mediated enhancement of Eo/B CFU. 
  The kinetics of IL-5-induced GATA-1 expression have 
not been previously described. The promoter region of the 
IL-5 receptor contains binding sites for different transcrip-
tion factors, Ap1, AP-1, GATA-1, and PU.1 [36]. GATA In Vitro Effects of Budesonide on Eosinophil-Basophil Lineage Commitment  The Open Respiratory Medicine Journal, 2008, Volume 2    65 
transcription factors are a family of factors with a conserved 
zinc-finger domain that bind DNA consensus GATA se-
quences [37]. GATA-1 is expressed in erythroid cells, mega-
karyocytes, mast cells and eosinophils [38] as well as Sertoli 
cells, and is a key transcription factor for the development of 
eosinophils from CD34
+ hemopoietic progenitors. CD34
+ CB 
cells infected with an adenoviral vector containing GATA-1 
were strongly supported into eosinophil differentiation. 
Moreover, the deletion of high-affinity GATA-binding sites 
within the GATA-1 promoter in a murine model leads to 
eosinophil loss [39]. Our results show that the peak of 
GATA-1 mRNA expression was at 2 days of IL-5 incuba-
tion. The addition of BUD led to a GATA-1 mRNA peak at 
a much earlier time point (4 hours); this may explain the 
increase in Eo/B CFU consistently seen with in vitro BUD 
whether CB or bone marrow progenitors are utilized. Similar 
glucocorticoid effects on transcription factor-induced cyto-
kine expression have been described elsewhere [40]. In stud-
ies of stem-cell factor (SCF) regulation, the addition of BUD 
lead to a decrease in SCF mRNA expression while the addi-
tion of IL-1 resulted in an initial increase, which could be 
blocked by RU486, a glucocorticoid antagonist [40]. The 
authors speculated that potentiation by BUD of the 
IL-1induced SCF expression was related to an increased 
stability of SCF mRNA, and increased SCF gene transcrip-
tion. A similar explanation may underlie BUD potentiation 
of IL-5-induced GATA-1 mRNA expression in our study. 
Moreover, since GATA-1 is auto-regulatory, in that it can 
positively regulate its own promoter [41,42], an earlier peak 
of GATA-1 expression and activity induced by BUD could 
be amplified and lead to increases in Eo/B differentiation. 
CONCLUSION 
  In summary, we have demonstrated that BUD leads to an 
increase in Eo/B lineage commitment. While the reasons for 
this may be multiple, we have shown that an initial increase 
in GATA-1 mRNA expression in IL-5-stimulated Eo/B pro-
genitors may underlie the phenomenon. Further studies to 
examine Eo/B lineage-specific transcription factor expres-
sion and regulation in Eo/B progenitors may clarify the role 
of corticosteroids in Eo/B differentiation, and lead to more 
rational therapy for allergic diseases. 
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